High Throughput Screening to Discover Chemical Probes of ASK1
高通量筛选发现 ASK1 化学探针
基本信息
- 批准号:8419212
- 负责人:
- 金额:$ 43.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-01-01 至 2015-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcademiaApoptosisBiochemicalBiological AssayBiologyCardiovascular DiseasesCardiovascular systemCell DeathCellsCellular StressChemicalsChemistryCherry - dietaryComplexCritical PathwaysDetectionDevelopmentDevelopment PlansDiseaseEnsureFamilyFloridaFoundationsFutureGenerationsGeneticGoalsHeart HypertrophyHumanImageInflammatoryInhibitory Concentration 50InvestigationKnockout MiceLaboratoriesLeadLegal patentLengthLibrariesLiteratureMAP2K6 geneMeasurementMeasuresMediatingMitogen-Activated Protein KinasesMolecular ProbesMonitorNeurodegenerative DisordersPathway interactionsPharmaceutical ChemistryPhenotypePhosphorylationPhosphotransferasesPhysiologicalPhysiological ProcessesPhysiologyPlayPositioning AttributeProcessProtein-Serine-Threonine KinasesRadioactiveReactionResearchResearch InfrastructureResearch InstituteResearch PersonnelResearch ProposalsRheumatoid ArthritisRoleRunningSchemeSeriesSignal TransductionStressTalentsTestingTriagebasecytotoxiccytotoxicitydesigndrug discoveryfollow-uphigh throughput screeninghuman diseaseinhibitor/antagonistinorganic phosphatelead seriesmeetingsmemberminiaturizemouse modelnovelnovel therapeuticsprogramsresearch studyscaffoldscreeningsmall moleculesmall molecule librariestool
项目摘要
DESCRIPTION (provided by applicant): The stress-activated, apoptosis signal-regulating kinase (ASK1) plays important roles in several physiological and pathophysiological processes. In particular, genetic studies have shown that loss of this serine/threonine kinase ameliorates many of the phenotypes manifest in mouse models of rheumatoid arthritis, cardiac hypertrophy and neurodegenerative disorders. Notably, ASK1 is an eminently tractable target and selective small molecule inhibitors of ASK1 would provide valuable probes to further characterize ASK1-directed pathways. However, outside of the patent literature no ASK1 inhibitors are available to academia. Our research proposal fulfills all of the specifications of PAR-12-058, entitled "Solicitation of Assays for High Throughput Screening (HTS) to Discover Chemical Probes", where we will perform a HTS-campaign and will implement a rigorous research operating plan comprised of biochemical and cell-based assays to identify, confirm and validate selective small molecule ASK1 inhibitors. Specifically, we have exploited our recent enzymatic studies of the active ASK1 complex to develop a new 384-well compatible, homogenous ASK1 biochemical assay. Furthermore, we have validated this assay using the Sigma-LOPAC (Library of Pharmacologically Active Compounds) library. In the studies of Aim 1, we will miniaturize this assay to 1536- format and perform a HTS campaign against The Scripps Research Institute's (TSRI) 650,000 small molecule compound library. In Aim 2 "hits" identified in the primary screen will be confirmed and further evaluated to: i) triage false positives; ii) confirm "hits" using an
orthogonal biochemical assay, iii) rank order the biochemical activity of "hits" based upon the concentration needed to inhibit 50% (IC50) of ASK1 kinase activity; and iv) triage scaffolds for chemical tractability prior to cell-based assay analyses. In Aim 3, we will test the cellular potency of our ASK1 inhibitors using a substrate phosphorylation assay that specifically quantifies the phosphorylation state of MKK6, a direct substrate of ASK1. Cell penetrant molecules will then be assessed for cytotoxicity using an apoptosis assay and nontoxic compounds will be tested in multi-parametric, functional, cell-based imaging assays to determine if lead ASK1 inhibitors can indeed protect against ASK1-mediated cell death. Finally, we will assess the kinase selectivity of our top lead inhibitors against a panel of 300 kinases (Reaction Biology Corp). Our Multi-PI research team at the Scripps Florida campus of TSRI has both the expertise and infrastructure to perform these experiments, and we submit that the successful completion of our studies will identify a series of new, potent and selective molecular probes that will help define the role(s) that ASK1 plays in normal physiological processes as well as in disease states.
描述(由申请人提供):应激激活的凋亡信号调节激酶(ASK 1)在几种生理和病理生理过程中起重要作用。特别是,遗传研究表明,这种丝氨酸/苏氨酸激酶的损失改善了类风湿性关节炎,心脏肥大和神经退行性疾病的小鼠模型中表现出的许多表型。值得注意的是,ASK 1是一个非常容易处理的靶标,ASK 1的选择性小分子抑制剂将提供有价值的探针,以进一步表征ASK 1介导的途径。然而,在专利文献之外,学术界没有可获得的ASK 1抑制剂。我们的研究提案符合PAR-12-058的所有规范,标题为“高通量筛选(HTS)发现化学探针的试验征集”,我们将进行HTS活动,并将实施严格的研究操作计划,包括生物化学和基于细胞的试验,以识别,确认和验证选择性小分子ASK 1抑制剂。具体来说,我们利用我们最近的活性ASK 1复合物的酶促研究,开发了一种新的384孔相容性,同质ASK 1生化测定。此外,我们还使用Sigma-LOPAC(药理活性化合物库)库验证了该试验。在目标1的研究中,我们将把该测定法扩展到1536格式,并对斯克里普斯研究所(TSRI)的650,000小分子化合物库进行HTS活动。在目标2中,将确认并进一步评估在初级筛选中识别的“命中”,以:i)分类假阳性; ii)使用
正交生物化学测定,iii)基于抑制50%(IC 50)ASK 1激酶活性所需的浓度,对“命中物”的生物化学活性进行排序;和iv)在基于细胞的测定分析之前,对支架进行分类以用于化学易处理性。在目标3中,我们将使用底物磷酸化测定来测试我们的ASK 1抑制剂的细胞效力,该测定特异性地定量MKK 6(ASK 1的直接底物)的磷酸化状态。然后将使用细胞凋亡测定法评估细胞渗透剂分子的细胞毒性,并在多参数、功能性、基于细胞的成像测定法中测试无毒化合物,以确定先导ASK 1抑制剂是否确实可以防止ASK 1介导的细胞死亡。最后,我们将评估我们的顶级先导抑制剂对一组300种激酶的激酶选择性(Reaction Biology Corp)。我们在TSRI的Scripps佛罗里达校区的Multi-PI研究团队拥有进行这些实验的专业知识和基础设施,我们认为我们研究的成功完成将确定一系列新的,有效的和选择性的分子探针,这将有助于确定ASK 1在正常生理过程中以及疾病状态中所起的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Derek Ronald Duckett其他文献
Derek Ronald Duckett的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Derek Ronald Duckett', 18)}}的其他基金
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
开发 CDK12 抑制剂以克服 HER2 和 KRAS 驱动的乳腺癌和肺癌的治疗耐药性
- 批准号:
10533580 - 财政年份:2021
- 资助金额:
$ 43.69万 - 项目类别:
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
开发 CDK12 抑制剂以克服 HER2 和 KRAS 驱动的乳腺癌和肺癌的治疗耐药性
- 批准号:
10737865 - 财政年份:2021
- 资助金额:
$ 43.69万 - 项目类别:
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
开发 CDK12 抑制剂以克服 HER2 和 KRAS 驱动的乳腺癌和肺癌的治疗耐药性
- 批准号:
10703529 - 财政年份:2021
- 资助金额:
$ 43.69万 - 项目类别:
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
开发 CDK12 抑制剂以克服 HER2 和 KRAS 驱动的乳腺癌和肺癌的治疗耐药性
- 批准号:
10449355 - 财政年份:2021
- 资助金额:
$ 43.69万 - 项目类别:
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
开发 CDK12 抑制剂以克服 HER2 和 KRAS 驱动的乳腺癌和肺癌的治疗耐药性
- 批准号:
10686136 - 财政年份:2021
- 资助金额:
$ 43.69万 - 项目类别:
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
开发 CDK12 抑制剂以克服 HER2 和 KRAS 驱动的乳腺癌和肺癌的治疗耐药性
- 批准号:
10279337 - 财政年份:2021
- 资助金额:
$ 43.69万 - 项目类别:
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma
转录和表观遗传适应作为套细胞淋巴瘤的新治疗漏洞
- 批准号:
10358557 - 财政年份:2020
- 资助金额:
$ 43.69万 - 项目类别:
Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma
转录和表观遗传适应作为套细胞淋巴瘤的新治疗漏洞
- 批准号:
10579255 - 财政年份:2020
- 资助金额:
$ 43.69万 - 项目类别:
Development of in vivo active small molecule selective inhibitors of ASK1
ASK1 体内活性小分子选择性抑制剂的开发
- 批准号:
9218535 - 财政年份:2016
- 资助金额:
$ 43.69万 - 项目类别:
High Throughput Screening to Discover Chemical Probes of ASK1
高通量筛选发现 ASK1 化学探针
- 批准号:
8788282 - 财政年份:2013
- 资助金额:
$ 43.69万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Optogenetic and Biochemical Studies of Novel Roles of beta-Catenin Modulation/Addiction in Neuronal Differentiation and Apoptosis
β-连环蛋白调节/成瘾在神经元分化和细胞凋亡中新作用的光遗传学和生化研究
- 批准号:
8984020 - 财政年份:2015
- 资助金额:
$ 43.69万 - 项目类别:
Proteomic and Biochemical Studies of Bax Regulatory Proteins in Apoptosis
Bax 细胞凋亡调节蛋白的蛋白质组学和生化研究
- 批准号:
8051912 - 财政年份:2010
- 资助金额:
$ 43.69万 - 项目类别:
Structural/Biochemical Analysis: Apoptosis in C. elegans
结构/生化分析:线虫细胞凋亡
- 批准号:
7175363 - 财政年份:2005
- 资助金额:
$ 43.69万 - 项目类别:
Biochemical and structural characterisation of key protein interactions during apoptosis
细胞凋亡过程中关键蛋白质相互作用的生化和结构表征
- 批准号:
nhmrc : 356255 - 财政年份:2005
- 资助金额:
$ 43.69万 - 项目类别:
Career Development Fellowships
Structural/Biochemical Analysis: Apoptosis in C. elegans
结构/生化分析:线虫细胞凋亡
- 批准号:
6850982 - 财政年份:2005
- 资助金额:
$ 43.69万 - 项目类别:
Structural/Biochemical Analysis: Apoptosis in C. elegans
结构/生化分析:线虫细胞凋亡
- 批准号:
7345488 - 财政年份:2005
- 资助金额:
$ 43.69万 - 项目类别:
Structural/Biochemical Analysis: Apoptosis in C. elegans
结构/生化分析:线虫细胞凋亡
- 批准号:
7011254 - 财政年份:2005
- 资助金额:
$ 43.69万 - 项目类别:
MITOCHONDRIA, OXIDATIVE STRESS AND NEURONAL APOPTOSIS: BIOCHEMICAL, CELLULAR AND PHARMACOLOGICAL APPROACHES
线粒体、氧化应激和神经元凋亡:生物化学、细胞和药理学方法
- 批准号:
nhmrc : 194323 - 财政年份:2002
- 资助金额:
$ 43.69万 - 项目类别:
NHMRC Project Grants
BIOCHEMICAL DISSECTION OF P53 DEPENDENT APOPTOSIS PATHW
P53 依赖性细胞凋亡途径的生化剖析
- 批准号:
2885057 - 财政年份:1999
- 资助金额:
$ 43.69万 - 项目类别:
GENETIC AND BIOCHEMICAL EVENTS IN AB-INDUCED APOPTOSIS
AB 诱导的细胞凋亡中的遗传和生化事件
- 批准号:
2001588 - 财政年份:1995
- 资助金额:
$ 43.69万 - 项目类别: